Calla Lily Clinical Care Doses First Patients in FREEDOM Clinical Trial for Intravaginal Drug Delivery of Progesterone
Calla Lily Clinical Care has initiated dosing for the FREEDOM clinical trial, which is evaluating the effectiveness of a 400mg progesterone formulation, Callavid®, in patients suffering from luteal phase insufficiency. This condition can lead to low progesterone levels, increasing the risk of infertility and recurrent miscarriage.
LONDON–(BUSINESS WIRE)–Calla Lily Clinical Care, a women’s health-focused medical technology company, today announced dosing of the first patients in the FREEDOM clinical trial. The study, funded by the National Institute for Health and Care Research (NIHR), is evaluating 400mg progesterone Callavid® in patients diagnosed with luteal phase insufficiency, a condition where progesterone levels may be too low to support early pregnancy, increasing risk of infertility and recurrent miscarriage. C